Home › Ewing Sarcoma
Ewing Sarcoma clinical trials recruiting in the U.S.
34 studies for Ewing Sarcoma are recruiting participants at sites across the United States.
Cities with the most studies
- New York City, NY8 studies
- Houston, TX7 studies
- Memphis, TN7 studies
- Philadelphia, PA7 studies
- Los Angeles, CA6 studies
- Washington, DC6 studies
- Aurora, CO6 studies
- Boston, MA6 studies
- Birmingham, AL5 studies
- Atlanta, GA5 studies
- Cincinnati, OH5 studies
- Nashville, TN4 studies
- Gainesville, FL4 studies
- St. Petersburg, FL4 studies
- Phoenix, AZ4 studies
- Dallas, TX4 studies
- Salt Lake City, UT4 studies
- Tampa, FL4 studies
- Baltimore, MD4 studies
- Columbus, OH4 studies
- Grand Rapids, MI4 studies
- Ann Arbor, MI4 studies
- Hartford, CT3 studies
- Miami, FL3 studies
- St. Louis, MO3 studies
- Harrisburg, PA3 studies
- The Bronx, NY3 studies
- Greenburgh, NY3 studies
- Minneapolis, MN3 studies
- Orange, CA3 studies
- Portland, OR3 studies
- San Francisco, CA3 studies
By state
- Alabama5 studies
- Arizona4 studies
- California12 studies
- Colorado6 studies
- Connecticut4 studies
- District of Columbia6 studies
- Florida7 studies
- Georgia5 studies
- Maryland4 studies
- Massachusetts6 studies
- Michigan9 studies
- Minnesota5 studies
- Missouri4 studies
- New Jersey4 studies
- New York12 studies
- Ohio9 studies
- Oregon3 studies
- Pennsylvania10 studies
- Tennessee11 studies
- Texas10 studies
- Utah4 studies
- Wisconsin3 studies
Recently updated studies
Silmitasertib (CX-4945) in Combination With Chemotherapy for Relapsed Refractory Solid Tumors
RecruitingPhase 1/2
Up to age 30 · All sexes · Updated Nov 12, 2026 · NCT06541262A Phase 1/1B Study of ST-01156, a Small Molecule RBM39 Degrader, in Patients With Advanced Solid Malignancies
RecruitingPhase 1
Ages 16 and older · All sexes · Updated Nov 12, 2026 · NCT07197554Study of Lurbinectedin Monotherapy in Pediatric and Young Adult Participants With Relapsed/Refractory Ewing Sarcoma
RecruitingPhase 1/2
Ages 2 to 30 · All sexes · Updated Nov 5, 2026 · NCT05734066Substudy 01A: Zilovertamab Vedotin in Pediatric and Young Adult Participants With Hematologic Malignancies or Solid Tumors (MK-9999-01A/LIGHTBEAM-U01)
RecruitingPhase 1/2
6 Months – 25 Years · All sexes · Updated Oct 30, 2026 · NCT06395103Evaluation of Xaluritamig in Adults, Adolescents and Children With Relapsed or Refractory Ewing Sarcoma (EWS)
RecruitingPhase 1
Ages 2 and older · All sexes · Updated Oct 29, 2026 · NCT07297979Alpha/Beta CD19+ Depleted Haploidentical Transplantation + Zometa for Pediatric Hematologic Malignancies and Solid Tumors
RecruitingPhase 1
7 Months – 21 Years · All sexes · Updated Oct 27, 2026 · NCT02508038XL092 (Zanzalintinib) for the Treatment of Patients With Metastatic or Unresectable Leiomyosarcoma, Bone Sarcoma or Translocation-associated Soft Tissue Sarcoma
RecruitingPhase 2
Ages 18 and older · All sexes · Updated Oct 13, 2026 · NCT06571734Phase 1 Dose-escalating Study of MM-398 (Irinotecan Sucrosofate Liposome Injection) Plus Intravenous Cyclophosphamide in Recurrent or Refractory Pediatric Solid Tumors
RecruitingPhase 1
12 Months – 20 Years · All sexes · Updated Oct 8, 2026 · NCT02013336Eflornithine (DFMO) for Ewing Sarcoma and Osteosarcoma
RecruitingPhase 2
Ages 0 to 50 · All sexes · Updated Oct 6, 2026 · NCT07321912Biologically-Adapted, Dose-Escalated Radiotherapy for the Treatment of Ewing Sarcoma, BEAR Trial
Recruiting
Ages 2 and older · All sexes · Updated Oct 6, 2026 · NCT07188532Metastatic Ewing's Trial Testing Schedule Enhancement to Improve Outcomes
RecruitingPhase 1
Ages 1 and older · All sexes · Updated Sep 25, 2026 · NCT07194044Phase 1 Study of INBRX-109 in Subjects With Locally Advanced or Metastatic Solid Tumors Including Sarcomas
RecruitingPhase 1
Ages 12 to 85 · All sexes · Updated Sep 8, 2026 · NCT03715933Eflornithine (DFMO) and AMXT 1501 for Neuroblastoma, CNS Tumors, and Sarcomas
RecruitingPhase 1/2
Up to age 26 · All sexes · Updated Sep 3, 2026 · NCT06465199Cabozantinib With Ifosfamide in Relapsed/Refractory Sarcomas
RecruitingPhase 1
Ages 5 to 40 · All sexes · Updated Sep 3, 2026 · NCT06156410Lurbinectedin in FET-Fused Tumors
RecruitingPhase 1/2
Ages 10 and older · All sexes · Updated Sep 2, 2026 · NCT05918640Tegavivint for the Treatment of Recurrent or Refractory Solid Tumors, Including Lymphomas and Desmoid Tumors
RecruitingPhase 1/2
12 Months – 30 Years · All sexes · Updated Aug 25, 2026 · NCT04851119Integration of Adaptive Proton Therapy in Pediatric Solid Tumors and Hodgkin's Lymphoma
Recruiting
All ages · All sexes · Updated Aug 21, 2026 · NCT07514819Selective Antigen Specific T Cells and CAR T Cells in Subjects With Relapsed/Refractory Embryonal Tumors (SABRE)
RecruitingPhase 1
Ages 1 to 23 · All sexes · Updated Aug 13, 2026 · NCT07172958Disulfiram With Copper Gluconate and Liposomal Doxorubicin in Treatment-Refractory Sarcomas
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Aug 6, 2026 · NCT05210374Feasibility Study on the Effect of a Methionine-Reduced Diet on Serum Levels in Pts w/ Solid Tumors
RecruitingEarly phase 1
Ages 18 and older · All sexes · Updated Jul 31, 2026 · NCT07628634Targeted Oligometastatic Radiation in Pediatric and Young Adult Patients With Soft Tissue and Bone Sarcoma
Recruiting
Up to age 39 · All sexes · Updated Jul 13, 2026 · NCT06796543Alpha/Beta T and B Cell Depletion With Zoledronic Acid for Solid Tumors
RecruitingPhase 1/2
6 Months – 25 Years · All sexes · Updated Jun 30, 2026 · NCT06625190Study of Onivyde With Talazoparib or Temozolomide in Children With Recurrent Solid Tumors and Ewing Sarcoma
RecruitingPhase 1/2
12 Months – 30 Years · All sexes · Updated May 19, 2026 · NCT04901702B7-H3-Specific Chimeric Antigen Receptor Autologous T-Cell Therapy for Pediatric Patients With Solid Tumors (3CAR)
RecruitingPhase 1
Up to age 21 · All sexes · Updated May 19, 2026 · NCT04897321Assessment of Healing and Function After Reconstruction Surgery for Bone Sarcomas
RecruitingObservational study
Ages 4 and older · All sexes · Updated Apr 17, 2026 · NCT03442465From ClinicalTrials.gov, data retrieved Nov 15, 2026. Each study sets its own eligibility; the study team decides who can join.